Compare Incyte Corporation (INCY) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Veritone Inc — how do they compare? Incyte Corporation trades at $117.94 (market cap $23.11B), while Veritone Inc trades at $1.09 (market cap $97.60M). The key difference: Incyte Corporation is far larger — about 236.8× Veritone Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| INCY | VERI | |
|---|---|---|
Market Cap | $23.11B | $97.60M |
Sector | Health | Technology |
52-Week High | $118.52 | $8.39 |
52-Week Low | $67.38 | $1.02 |
Enterprise Value | $19.13B | $129.63M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
VERI trades at $1.05, up 2.94% on the day, but remains in a bearish technical trend. The company reported a net loss of $111.73 million in 2025, with a negative net income margin of -123.76%, while revenue declined to $92.19 million. Multiple securities class action lawsuits, with a July 20, 2026 deadline, highlight significant legal and reputational risks stemming from alleged improper revenue accounting.
The outlook is highly speculative given severe profitability challenges and ongoing litigation. Analyst consensus is split between Buy and Hold, but fundamental weaknesses and legal overhangs present substantial downside risk. Investment suitability is limited to risk-tolerant investors monitoring resolution of legal issues and a path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
